ClinicalTrials.gg
RecruitingNCT07708571TYPERUpdated Jul 16, 2026

Evaluating the Effectiveness of Typology-based Coaching on Patients' Therapy Management

An interventional study of Typology-based coaching in HR+/HER2- Early Breast Cancer, sponsored by Institut fuer Frauengesundheit. Recruiting at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Institut fuer Frauengesundheit · Not applicable, Interventional, and Health services research

How we know · 2 judgments

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Nov 2025, registered Jul 2026).
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
548
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit — 5 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · Institut fuer Frauengesundheit.

Started
2025
the only one that year
No phase
2 of 10
2 open now
Registered
10th of 10
by date

Among the 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit, this one is the only one that started in 2025, is one of 2 with no phase, and was the 10th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the effect of patient education and patient typology-based coaching on therapy persistence in breast cancer patients taking ribociclib. Researchers will compare the time to permanent treatment discontinuation of patients receiving personalized coaching to the time to permanent treatment discontinuation of patients who only receive standard of care education and counselling, to see if adherence to treatment can be improved by personalized patient coaching.

03

Conditions studied

  • HR+/HER2- Early Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant provides written prior to the beginning of trial-specific procedures.
  • Patients must be aged ≥18 years on the day of signing informed consent.
  • Participant has confirmed primary invasive adenocarcinoma of the breast.
  • Participant has a histologically and/or cytologically confirmed diagnosis of ER-positive and/or progesterone receptor-positive breast cancer based on the most recently analyzed tissue sample tested by a local laboratory.
  • Participant has HER2neg breast cancer defined as a negative ISH test or an IHC status of 0, 1+, or 2+. If the IHC is 2+, a negative ISH (e.g., FISH, CISH, SISH, or DISH) test is required by local laboratory testing and based on the most recently analyzed tissue sample.
  • Indication for treatment with ribociclib in combination with an aromatase inhibitor for early breast cancer according to the valid SmPC.
  • Participant has adequate organ function amenable for treatment with ribociclib as assessed by a local laboratory.
  • Female participants of must have had a hysterectomy or be willing to use highly effective methods of and have a confirmed negative pregnancy test as assessed by local in-house standard.
  • Participant is willing and able to comply with scheduled visits, treatment plans, and other trial procedures.

Exclusion criteria

Exclusion Criteria:

  • Patients with distant of breast cancer beyond regional lymph nodes (stage IV according to AJCC 8th edition) and/or evidence of recurrence after curative surgery.
  • Patients with serious preexisting medical condition(s) that would preclude participation in this study.
  • Women who are pregnant or lactating.
  • Patients with active bacterial infections (requiring IV antibiotics at time of initiating study treatment), fungal infections, or detectable viral infections (e.g., known positivity or known active or C, such as hepatitis B surface antigen-positive]).
  • Patients with a personal history in the past 5 years of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
  • Patients with against ribociclib according to the current SmPC.
  • Patients with to active substance of ribociclib, peanuts, soya or one of the other ingredients
  • Patients who are not eligible for the trial due to severe comorbidities other than those mentioned above or unavailability according to the treating physician.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
548 participants (estimated)

Study arms

  • Experimental
    Typology-based coaching

    Personalized therapy coaching based on patient typology

    Behavioral: Typology-based coaching

  • No intervention
    Standard of care patient counselling

    Standard of care therapy education and counselling

Interventions

  • BehavioralTypology-based coaching

    Standardized patient coaching based on the Multinational Association of Supportive Care in Cancer (MASCC) Oral Agent Teaching Tool© (MOATT)

This study also gives RibociclibStudies of RibociclibRibociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Time to discontinuation

    Time to permanent discontinuation of ribociclib therapy

    Time frame: From baseline up to end of study (max. 5 years)

Secondary outcomes

  1. Ribociclib persistence rate

    Ribociclib persistence rate (defined as ongoing ribociclib therapy)

    Time frame: At 6, 12 and 36 months after therapy start

07

Study locations

3 of 3 sites recruiting
  • Department of Gynecology and Obstetrics, Universitätsklinikum Augsburg
    Augsburg, Bavaria 86156, Germany
    Recruiting
  • Department of Obstetrics and Gynecology, Uniklinikum Erlangen
    Erlangen, Bavaria 91054, Germany
    Recruiting
  • MVZ Klinikum Aschaffenburg, Zweigstelle Hänatologie und Onkologie
    Hösbach, Bavaria 63768, Germany
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jun 2030, 55 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 55 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 16, 2026
StartActual
Nov 4, 2025
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2030
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07708571
Lead sponsor
Institut fuer Frauengesundheit
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Nov 4, 2025
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Jul 16, 2026

Study contacts

Institut für Frauengesundheit GmbH
Contact
typer@ifg-erlangen.de
+49 9131 91880613
Manfred Welslau, Dr. med.
principal investigator · MVZ Klinikum Aschaffenburg, Zweigstelle Hänatologie und Onkologie
Nina Ditsch, Prof. Dr. med.
principal investigator · Department of Gynecology and Obstetrics, Universitätsklinikum Augsburg

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion